Skip to main content
Premium Trial:

Request an Annual Quote

Vanderbilt Team Will Use Affy Arrays to Study HIV/AIDS, Cancer\

NEW YORK (GenomeWeb News) — The Vanderbilt-Ingram Cancer Center will use Affymetrix’s GeneChip microarrays in translational research projects studying cancer and HIV and AIDS, Affy said today.
 
Under the terms of the agreement, VICC and Vanderbilt University Medical Center will use Affy’s mitochondrial resequencing array 2.0 as a tool to research genetic variants that may make patients more susceptible to adverse effects of certain drugs.
 
For cancer, Affy said VICC hopes that the studies will reveal the molecular basis of diseases and differences at the genetic level that influence responses to therapies. For HIV/AIDS research, the study aims to help clinicians determine the best drug treatments in “affluent and resource-limited settings.”
 
Jeff Canter, a researcher at the Center for Human Genetics Research and Vanderbilt, said ongoing translational projects include cancer, HIV/AIDS drug toxicities,” and macular degeneration.
 
Financial terms of the agreement were not released.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.